Advertisement

Search Results

Advertisement



Your search for what matches 6139 pages

Showing 3951 - 4000


Expert Point of View: Taofeek Kunle Owonikoko, MD

Formal discussant Taofeek Kunle Owonikoko, MD, of Emory University School of Medicine, Atlanta, commented that this preliminary study looks promising for a new antibody-drug conjugate. “To me, what is intriguing about these data is the efficacy signal in the third-line setting, especially for the ...

Expert Point of View: Peter C. Enzinger, MD

Not so FAST? The study discussant Peter C. Enzinger, MD, Director of the Center for Esophageal and Gastric Cancer at Dana-Farber/Brigham and Women’s Cancer Center, Boston, viewed the findings of the FAST trial as promising but voiced several considerations, as did Gulam A. Manji, MD, PhD,...

colorectal cancer

Influence of Age and Comorbidities on Rates of Colorectal Cancer Screening in the Elderly

Colorectal cancer (CRC) is a common and costly disease, largely of the elderly, with nearly 25% of cases diagnosed among patients aged 75–84 years. However, but the guidelines for CRC screening of Americans aged 75 or older vary according to the source. In a study published by Klabunde et al...

ASCO Announces New Award Honoring Visionary Leader Allen S. Lichter, MD, FASCO

During the 2016 Annual Meeting, ASCO announced the creation of the Allen S. Lichter Visionary Leader Award to recognize ASCO members who have transformed the oncology field or significantly advanced the mission of ASCO, the Conquer Cancer Foundation, or CancerLinQ, LLC, through their leadership,...

Expert Point of View: Patricia Ganz, MD

Moderating a press conference where Dr. Chen presented his study findings, Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, called this study “interesting and ­important.” She continued:...

breast cancer

Trastuzumab Biosimilar Shows Efficacy and Safety Comparable to Reference Product in Phase III HERITAGE Trial

A new biosimilar version of the monoclonal antibody trastuzu­mab (Herceptin) is getting close to the finish line in the race to develop biosimilars in oncology. The new antibody, MYL-1401O, demonstrated comparable efficacy and safety compared with trastuzumab as front-line treatment of women with...

cost of care
issues in oncology

ASCO Releases the Updated Version of Its Value Framework

Last June, ASCO published its initial concept for a value framework in the Journal of Clinical Oncology (JCO).1 The framework, developed by ­ASCO’s Value in Cancer Care Task Force, is designed to provide a standardized approach to assist physicians and patients in assessing the “value” of a new...

issues in oncology

ASCO 2016: Hispanic and Black Young Adults With Cancer May Be More Likely to Die of Their Disease

Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented by Colton et al at the 2016 ASCO Annual Meeting (Abstract 6557). The finding is...

ASCO Updates Value in Cancer Care Framework

On May 31, 2016, ASCO published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al,1 defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms...

Breast Density Legislation: An Opportunity for Better Risk Assessment

Dense breasts are not an automatic indication for additional imaging. Instead, breast density generally provides an opportunity for improved risk assessment, according to Kevin Hughes, MD, of Massachusetts General Hospital, Boston. “More than 20 states have mandated that women be informed of...

The Importance of Listening to Patients

My experience with cancer, or more accurately, cancers, is complicated. In 2002, after returning from a medical mission to Honduras, I noticed a bean-sized lymph node above my left clavicle. As an oncology-certified nurse, I knew not to ignore any unusual nodules that pop up on the body and asked...

Rising

There were once two patients with leukemia. Other than their diagnoses and their ages, these two men had nothing in common. Meet Michael Michael was an artist—a sculptor. He had large, sensitive, blue eyes and a quiet, pensive manner. His acute observational power led him to ponder deep questions...

An Unusual Memoir of Cancer

“A book about the future must be written in advance. Later I won’t have the energy. So I will do it now.” So begins The Iceberg, a memoir set in Britain of a woman, Marion Coutts, whose husband was diagnosed with a brain tumor, which eventually killed him. Unfortunately, cancer memoirs flood the...

The Best HCAHPS Score: A Rodeo Invitation

An otherwise healthy, actively working, independent 60-year-old patient came to us with a several months’ history of abdominal pain. He had been seen by other physicians prior to coming to us for a second opinion. Our workup revealed a large cystic lesion emanating from the pancreas but involving ...

issues in oncology

Low-Dose Chemical Exposure and Cancer

According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true...

multiple myeloma

SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma

Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...

issues in oncology

American Cancer Society Report Assesses Progress Against Goals Set for Nation 25 Years Ago

A new report assesses how the nation fared against the ambitious goal set by the American Cancer Society (ACS) to reduce cancer death rates by 50% over 25 years ending in 2015. The report finds areas where progress was substantial, and others where it was not. Published by Byers et al,1 the report ...

ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships

ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined ­CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. ­CancerLinQ is already up and running in a number of practices and drawing on approximately...

prostate cancer

Prostate Cancer: Opinions Vary on Gleason Scores and Surgery

Diagnosis and treatment of prostate cancer have been the source of heated debate for decades, most of which has centered on the clinical value of the prostate-specific antigen (PSA) test. In 2012, the U.S Preventive Services Task Force (USPSTF) gave the PSA test a D grade, which discourages many...

Lung Cancer Alliance Supports Two Young Investigator Awards

The Conquer Cancer Foundation of ASCO (CCF) has received generous support from Lung Cancer Alliance to fund a 2016 and 2017 Young Investigator Award (YIA) in lung cancer. Lung Cancer Alliance has a more than 20-year history of working to save lives and advance research by empowering those living...

cns cancers

Combined-Modality Therapy for Low-Grade Gliomas: Balancing Toxicity, Delivery Logistics, and Survival Benefit

Low-grade gliomas account for 15% of all primary brain tumors and represent a heterogeneous group of glial neoplasms. Although these tumors have been termed low-grade, this is a misnomer, especially for some grade II gliomas, which may exhibit a more aggressive behavior and variable natural...

health-care policy

Statement From FDA Commissioner Robert Califf, MD, on the Release of the Final Individual Patient Expanded Access Form

On June 2, 2016, U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement on the release of the final individual patient expanded access form.  “Today, the FDA finalized its efforts to streamline the process used by physicians to request expanded...

supportive care

Providing Inpatient Physical Rehabilitation for Patients With Advanced Cancer

Guest Editor Physiatry in Oncology explores the benefits of cancer rehabilitation in oncology practice to screen survivors for physical and cognitive impairments along the care continuum to minimize survivors’ disability and maximize their quality of life. The column is guest edited by Sean Smith, ...

prostate cancer

Chemotherapy After Radical Prostatectomy May Benefit African Americans and High-Risk Patients

A new U.S. Department of Veterans Affairs (VA) study suggests that African American men and men with a higher tumor stage may benefit from adjuvant chemotherapy following radical prostatectomy.1 According to prespecified analysis of these two “high–risk” subgroups, patients with ≥ T3b disease had a ...

health-care policy

ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention

As reported in the Journal of Clinical Oncology by Howard H. Bailey, MD, of the University of Wisconsin Carbone Cancer Center, and colleagues, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States.1  In the United...

It Started With Twitter: ASBrS Immediate Past-President, Deanna Attai, MD, Spearheads Patient-Centered Care

Breast surgeon Deanna Attai, MD, is a virtual mighty mouse as a spokesperson for her professional organization, the American Society of Breast Surgeons (ASBrS). She is as big on ideas as she is petite in stature and for actively tweeting on medical topics (@DrAttai). Assistant Clinical Professor...

Comparing Treatments by Efficacy, Toxicity, and Cost

Last year, five organizations introduced new methods to compare cancer treatments. For more on ASCO’s Value Framework, see page 120. The NCCN Evidence Blocks™ use a simple graphic to show experts’ ratings of systemic therapies in five areas: efficacy, safety, quality and quantity of evidence,...

issues in oncology

How Will Value Framework Tools Be Used in Everyday Practice?

Value framework tools made a splash in 2015, with five different groups unveiling methods to help physicians and patients compare therapies based on efficacy, toxicity, and/or cost. Now these potential users are beginning to examine and debate the tools, including how and whether they will work in...

health-care policy

ASCO Urges Centers for Medicare & Medicaid Services to Withdraw Medicare Part B Demo in Formal Comments

ASCO President Julie M. Vose, MD, MBA, FASCO, issued this statement on May 10. “In comments1 submitted yesterday to the Centers for Medicare & Medicaid Services (CMS), ASCO underscored the urgent need to advance a more fair and responsible payment system for oncology than what is proposed in...

breast cancer
global cancer care

Rising Breast Cancer Incidence in Sub-Saharan Africa: Challenges and Opportunities

The incidence of new cases of breast cancer in low- and middle-income countries, particularly in sub-Saharan ­Africa, is rising, and it will take a concerted effort from the international cancer community to counteract this troubling upward trend. It has been estimated that of the 15 million cancer ...

Extending ASCO’s Influence Globally to Improve Patient Care

On June 27, 2016, Clifford A. Hudis, MD, FACP, FASCO, will begin his tenure as Chief Executive Officer of ASCO, succeeding Allen S. Lichter, MD, FASCO, who presided over the Society and the Conquer Cancer Foundation of ASCO since 2006. Dr. Hudis’ dedication to ASCO dates back more than 25 years...

ASCO Announces New Award Honoring Visionary Leader Allen S. Lichter, MD, FASCO

During the 2016 Annual Meeting, ASCO announced the creation of the Allen S. Lichter Visionary Leader Award to recognize ASCO members who have transformed the oncology field or significantly advanced the mission of ASCO, the Conquer Cancer Foundation, or CancerLinQ, LLC, through their leadership,...

leukemia
cost of care

ASCO 2016: Patients With Cancer With ACA Policies Swiftly Reach Out-of-Pocket Caps

Duke Cancer Institute researchers have found that a hypothetical leukemia patient buying the life-extending drug therapy for his condition would reach his annual out-of-pocket maximum in a month on most of the bronze policies and half of the silver policies offered through the Affordable Care Act...

ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships

ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately...

solid tumors

ASCO 2016: Liquid Biopsy May Help Guide Treatment Decisions for Patients With Advanced Solid Tumors

A large-scale genomic analysis found that patterns of genetic changes detected in blood samples (liquid biopsy) closely mirror those identified in traditional tumor biopsy. With blood samples from more than 15,000 patients and 50 different tumor types, this is one of the largest cancer genomics...

breast cancer

ASCO 2016: Biosimilar Shows Comparable Efficacy and Safety to Trastuzumab in HER2-Positive Metastatic Breast Cancer

A biosimilar trastuzumab antibody (MYL-1401O) is comparable in efficacy and safety to trastuzumab (Herceptin) in women with HER2-positive advanced breast cancer, according to a randomized phase III study. The response rates were comparable among women who received trastuzumab and among...

health-care policy

Statement from FDA Commissioner Robert Califf, MD, on the Release of the Final Individual Patient Expanded Access Form

“Today, the U.S. Food and Drug Administration (FDA) finalized its efforts to streamline the process used by physicians to request expanded access, often called ‘compassionate use,’ to investigational drugs and biologics for their patients. As a physician, I understand the...

issues in oncology

ASCO Value Framework Update: A Statement by Julie M. Vose, MD, MBA, FASCO

ASCO today published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al in the Journal of Clinical Oncology, defines value as a combination of clinical benefit, side effects, and...

cns cancers

Play-Based Procedural Preparation May Aid Children Undergoing Cranial Radiation Therapy

Play-based procedural preparation not only helps children cope with the stress and anxiety of radiation therapy, but can also help reduce the amount of sedation used and cut costs, according to a study from the Child Life Program at St. Jude Children’s Research Hospital. The study was...

Colleagues Tip Their Hats to Allen S. Lichter, MD, FASCO

After serving as ASCO’s CEO for 10 years, Allen S. Lichter, MD, FASCO, is stepping down. Dr. Lichter, who has been an ASCO member since 1980, has served the Society in numerous capacities. Along with his distinguished career at ASCO, Dr. Lichter is a nationally recognized radiation oncologist,...

Surgical Oncologist Suzanne L. Topalian, MD, Shines at the Forefront of Groundbreaking Research in Cancer Immunotherapy

Nationally recognized surgical oncologist and researcher Suzanne L. Topalian, MD, had an early interest in the arts as well as science and decided to major in English upon entering Wellesley College in Wellesley, Massachusetts. “I wanted to keep all my options open, so I also enrolled in a pre-med...

Noted Gastrointestinal Oncologist Leonard Saltz, MD, Tempers Optimism With Reality and Factors Cost Into the Equation of Value in Cancer Care

Leonard Saltz, MD, was born in New York, New York, and reared in Westchester County, in the suburbs of the City. Terrance Archer, his high-school biology teacher, whom Dr. Saltz described as a “force of nature,” a wonderful human being, and a major role model, influenced his nascent curiosity in...

In Memoriam

The ASCO Post remembers the following specialists in oncology who passed away in 2015–2016. Please write to editor@ASCOPost.com to recognize and pay tribute to others in a future issue. Mark R. Green, MD January 3, 1945–February 23, 2015 “Few people have impacted cancer clinical research in the...

Physician-Researcher Carolyn Jean Presley, MD, Envisions Enhancing Geriatric Oncology

Carolyn Jean Presley, MD, a Robert Wood Johnson Foundation clinical scholar in medical oncology at the Yale Cancer Center, was born in Duluth, Minnesota, which hugs the north shore of Lake Superior, making it one of the nation’s coldest cities during its long winters. She grew up the middle child...

A Pioneer in Lung Cancer Research, James L. Mulshine, MD, Champions Early Population-Based Lung Cancer Screening

A neighborhood doctor who told a good story was an unwitting mentor to internationally regarded lung cancer expert James L. Mulshine, MD. Born in Elizabeth, New Jersey, Dr. Mulshine relocated with his family to West Hartford, Connecticut, when he was a year old, and except for a brief hiatus on...

With a Strong Personal Connection to His Patients, Stephen P. Hunger, MD, Strives for a Cure for All Children With Leukemia

Nationally regarded children’s cancer specialist Stephen P. Hunger, MD, was born and reared in South Windsor, a small suburb of Hartford, Connecticut. Dr. Hunger grew up in the mid-1960s and 1970s, and in his words, “South Windsor was a pretty homogeneous experience. There wasn’t really any ethnic...

International Authority on Radiation Effects, Robert Peter Gale, MD, PhD, Has Pushed Scientific Boundaries in Search of Answers

It is widely reported that the first use of sargramostim (Leukine) in humans (granulocyte macrophage colony-stimulating factor; GM-CSF) was to treat victims of the Goiânia, Brazil, radiation accident in 1987. However, recently declassified documents show that sargramostim was first used a year...

With an Illustrious Career in Breast Oncology, Daniel F. Hayes, MD, FASCO, Follows in the Footsteps of Giants as ASCO President-Elect

ASCO President-Elect Daniel F. Hayes, MD, FASCO, was born in Shelbyville, Indiana, a small city in the center of the state. “My dream was to become a high school basketball and track and field coach; my older brother wanted to be a doctor, and his ambitions also began in first grade,” revealed Dr....

Allen S. Lichter, MD, FASCO, Reflects on His Career Path and His Tenure as ASCO CEO, and Predicts a Bright Future for Radiation Oncology

Choosing a career path is one of life’s most challenging decisions, but for Allen S. Lichter, MD, FASCO, deciding to become a doctor was inherently natural. He was born with a great mentor and role model: his father. “I was born and raised in Detroit. My father was a general practitioner in...

survivorship
symptom management

Monitoring Survivors of Childhood Cancers for Late Effects of Treatment

This past January, ASCO held its inaugural Cancer Survivorship Symposium, which brought together the fields of medical oncology and primary care to address the critical need for coordinated care for cancer survivors. Among the presenters at the symposium was Smita Bhatia, MD, MPH, who gave the...

Advertisement

Advertisement




Advertisement